1 lized circulating insulin by injection of an insulin antibody.

2 proterenol and PD98059, but not those of the insulin antibody.

3 rformed by electrophoretically sampling anti-insulin antibody (Ab), fluorescein isothiocyanate-labele

4 a, weight, lipid levels, pulmonary function, insulin antibody binding, and adverse events.

5 cein isothiocyanate-labeled insulin and anti-insulin antibody for 60 s.

6 cein isothiocyanate-labeled insulin and anti-insulin antibody for a competitive immunoassay.

7 ation between pulmonary function changes and insulin antibody generation.

8            In patients with type 1 diabetes, insulin antibodies (IA), altering the pharmacokinetics o

9 is is shown for selective sensing of an anti-insulin antibody in the presence of its IgG isotype.Effi

10 rituximab not only blocks the acquisition of insulin antibodies induced by insulin administration and

11                                 By contrast, insulin antibody levels remained low for the first 2 wk

12          Spirometry tests were conducted and insulin antibody levels were measured throughout the stu

13 f MNP-serum insulin conjugate to the surface insulin-antibody on PGE/MWNT/Py electrodes.

14                                       Either insulin antibody or isoproterenol treatment induced the

15 various insulin analogs to a monoclonal anti-insulin antibody, thus providing a comparison with the p

16 tor memory cells is directly correlated with insulin antibody titers, suggesting insulin-specific T-

17 islet supernatant was reduced by 75% by anti-insulin antibody treatment.

18 te electrodes (PGE/MWNT/Py) to which an anti-insulin antibody was covalently attached.

19 oglycemia, mild weight gain, mild cough, and insulin antibodies were more frequent with inhaled insul